secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0000950170-23-009478
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca reports Q4/FY2022 net loss of $135.3M/$242.8M; licensed naporafenib from Novartis, raised $100M equity
--------------------------------------------------------------------------------

- Net loss Q4 2022 $135.3M (incl. $100M in-process R&D for naporafenib license); FY2022 net loss $242.8M ($1.99/share).
- Cash, cash equivalents & marketable securities $435.6M at Dec 31, 2022; expected runway into H2 2025.
- Completed $100M underwritten equity offering (15.4M shares at $6.50) in Dec 2022 concurrent with naporafenib license.
- Multiple data readouts planned in 2023 for ERAS-007, ERAS-601, ERAS-801; naporafenib Phase 1b (SEACRAFT-1) starts H2 2023.
- R&D expenses FY2022 $112.5M (up 52% YoY) driven by license payments and clinical progress.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023009478/0000950170-23-009478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023009478/eras-20230323.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer